Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
Devaki Shilpa Surasi(The University of Texas MD Anderson Cancer Center), Morand Piert, Ian Cox(The University of Texas MD Anderson Cancer Center), Mary A. Lokuta, Phillip H. Kuo(Knowledge Unlatched (Germany)), Michael L. Cher(The Barbara Ann Karmanos Cancer Institute), Michael N. Ferrandino, Shreyas Joshi, David Gauden(Emory University), Isuru Jayaratna, William C. Lavely, Bridget F. Koontz(AdventHealth Orlando), Mohamad E. Allaf(Johns Hopkins University), Benjamin A. Gartrell, Benjamin Lowentritt, Peter Gardiner(University of Turku), Norbert Avril(University Hospitals of Cleveland), Lale Kostakoğlu, Tobias Maurer(Universität Hamburg), Ergela Hasa, R. H. C. Penny, Thomas Horn(Harvard University), David M. Schuster(Emory University), Diederik M. Somford(Canisius-Wilhelmina Ziekenhuis), Soroush Rais‐Bahrami(University of Alabama at Birmingham), Heather A. Jacene(Brigham and Women's Hospital), Dinko Franceschi, Kenneth Ogan, Ashutosh Tewari(Icahn School of Medicine at Mount Sinai), Pooya Iranpour, Lars Budäus, Jeffrey W. Nix, Mark T. Fleming(Virginia Oncology Associates), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Matthew F. Covington(Intermountain Healthcare), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Peter J. Boström(University of Turku), Ryan Avery, Phillip Davis, Matthew P. Miller, Matthew D. Kay, Matthias Eiber(University of California, Los Angeles), Mark A. Preston(Brigham and Women's Hospital), Brian T. Helfand(NorthShore University HealthSystem), Rick Hermsen, Helen Barker, David Josephson(Cedars-Sinai Medical Center), Albert Chau(Blue Earth Diagnostics (United Kingdom)), Diane Chisholm, Laurence Belkoff
Cited by 90
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Multiple loci identified in a genome-wide association study of prostate cancer
|Nature Genetics|2008|907
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654